Literature DB >> 25274888

Detection of subclinical synovitis with macrophage targeting and positron emission tomography in patients with rheumatoid arthritis without clinical arthritis.

Yoony Y J Gent1, Nazanin Ahmadi1, Alexandre E Voskuyl1, Nikie Hoetjes1, Cornelis van Kuijk1, Karin Britsemmer1, Franktien Turkstra1, Maarten Boers1, Otto S Hoekstra1, Conny J van der Laken2.   

Abstract

OBJECTIVE: To determine whether macrophage targeting by (R)-11C-PK11195 positron emission tomography (PET) can visualize subclinical joint inflammation in patients with rheumatoid arthritis (RA) without clinical arthritis during or after treatment, with flare as clinical outcome measure.
METHODS: (R)-11C-PK11195 PET and contrast-enhanced magnetic resonance imaging (MRI) of hands/wrists were performed in 29 patients with RA without clinical arthritis. (R)-11C-PK11195 PET uptake (semiquantitative score 0-3) in metacarpophalangeal, proximal interphalangeal, and wrist joints (i.e., 22 joints per patient) was scored and summed to obtain a cumulative PET score (range 0-66). Rheumatoid Arthritis Magnetic Resonance Imaging Scoring (RAMRIS) was performed on similar joints. Synovitis and bone marrow edema scores (>1) were summed to obtain a cumulative MRI score (range 0-288). Occurrence of flare was determined during 3-year followup.
RESULTS: Flare was observed in 17/29 patients (59%). (R)-11C-PK11195 PET showed enhanced tracer uptake in 16/29 patients (55%), of which 11 (69%) developed a flare. Highest cumulative PET scores (>6, n=3) corresponded with highest cumulative MRI scores (>39) and were related to development of flare in hands/wrists within 6 months. Cumulative PET scores of patients developing a flare were higher than those of patients without a flare [median (interquartile range) 2 (0-4.5) vs 0 (0-1), p<0.05]. In contrast, no significant differences were found between cumulative MRI scores of patients with and without a flare.
CONCLUSION: (R)-11C-PK11195 PET showed enhanced uptake, pointing to presence of subclinical synovitis in over half of patients without clinical arthritis. (R)-11C-PK11195 PET may be of value for prediction of exacerbation of RA, since cumulative PET scores > 1 were associated with development of flare within 3 years.

Entities:  

Keywords:  IMAGING; MACROPHAGE; POSITRON EMISSION TOMOGRAPHY; RHEUMATOID ARTHRITIS

Mesh:

Substances:

Year:  2014        PMID: 25274888     DOI: 10.3899/jrheum.140059

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

1.  Imaging disease activity of rheumatoid arthritis by macrophage targeting using second generation translocator protein positron emission tomography tracers.

Authors:  S T G Bruijnen; N J F Verweij; Y Y J Gent; M C Huisman; A D Windhorst; M Kassiou; P M van de Ven; A A Lammertsma; O S Hoekstra; A E Voskuyl; C J van der Laken
Journal:  PLoS One       Date:  2019-09-25       Impact factor: 3.240

2.  Quantitative Assessment of Arthritis Activity in Rheumatoid Arthritis Patients Using [11C]DPA-713 Positron Emission Tomography.

Authors:  Maqsood Yaqub; Nicki J F Verweij; Simone Pieplenbosch; Ronald Boellaard; Adriaan A Lammertsma; Conny J van der Laken
Journal:  Int J Mol Sci       Date:  2020-04-29       Impact factor: 5.923

3.  Quantifying disease activity in rheumatoid arthritis with the TSPO PET ligand 18F-GE-180 and comparison with 18F-FDG and DCE-MRI.

Authors:  Marius de Groot; Neel Patel; Roido Manavaki; Robert L Janiczek; Mats Bergstrom; Andrew Östör; Danielle Gerlag; Alexandra Roberts; Martin J Graves; Yakshitha Karkera; Disala Fernando; Prafull Mistry; Adam Walker; Nicolas Wisniacki; Tim D Fryer; Pilar Jimenez-Royo
Journal:  EJNMMI Res       Date:  2019-12-19       Impact factor: 3.138

4.  Preclinical Evaluation of a Novel 99mTc-Labeled CB86 for Rheumatoid Arthritis Imaging.

Authors:  Peng Liu; Tingting Wang; Rongshui Yang; Wentao Dong; Qiang Wang; Zhide Guo; Chao Ma; Weixing Wang; Huaibo Li; Xinhui Su
Journal:  ACS Omega       Date:  2020-11-30

5.  Early prediction of treatment response in rheumatoid arthritis by quantitative macrophage PET.

Authors:  Nicki Verweij; Gerben Zwezerijnen; Marieke Ter Wee; Jerney de Jongh; Maqsood Yaqub; Dirkjan van Schaardenburg; Adriaan Lammertsma; Alexandre Voskuyl; Willem Lems; Maarten Boers; Conny van der Laken
Journal:  RMD Open       Date:  2022-02

6.  Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study.

Authors:  Yoony Y J Gent; Marieke M Ter Wee; Alexandre E Voskuyl; Debby den Uyl; Nazanin Ahmadi; Cristina Dowling; Cornelis van Kuijk; Otto S Hoekstra; Maarten Boers; Willem F Lems; Conny J van der Laken
Journal:  Arthritis Res Ther       Date:  2015-09-25       Impact factor: 5.156

7.  The macrophage marker translocator protein (TSPO) is down-regulated on pro-inflammatory 'M1' human macrophages.

Authors:  Nehal Narayan; Harpreet Mandhair; Erica Smyth; Stephanie Georgina Dakin; Serafim Kiriakidis; Lisa Wells; David Owen; Afsie Sabokbar; Peter Taylor
Journal:  PLoS One       Date:  2017-10-02       Impact factor: 3.240

8.  In-vivo monitoring of anti-folate therapy in arthritic rats using [18F]fluoro-PEG-folate and positron emission tomography.

Authors:  Durga M S H Chandrupatla; Gerrit Jansen; Ricardo Vos; Mariska Verlaan; Qingshou Chen; Philip S Low; Albert D Windhorst; Adriaan A Lammertsma; Conny J van der Laken; Carla F M Molthoff
Journal:  Arthritis Res Ther       Date:  2017-05-31       Impact factor: 5.156

9.  First in man study of [18F]fluoro-PEG-folate PET: a novel macrophage imaging technique to visualize rheumatoid arthritis.

Authors:  Nicki J F Verweij; Maqsood Yaqub; Stefan T G Bruijnen; S Pieplenbosch; Marieke M Ter Wee; Gerrit Jansen; Qingshou Chen; Philip S Low; Albert D Windhorst; Adriaan A Lammertsma; Otto S Hoekstra; Alexandre E Voskuyl; Conny J van der Laken
Journal:  Sci Rep       Date:  2020-01-23       Impact factor: 4.379

Review 10.  Have (R)-[11C]PK11195 challengers fulfilled the promise? A scoping review of clinical TSPO PET studies.

Authors:  Fabien Chauveau; Guillaume Becker; Hervé Boutin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-08-13       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.